Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
By B. Escudier, J. Bellmunt, S. Négrier, E. Bajetta, B. Melichar, S. Bracarda, A. Ravaud, S. Golding, S. Jethwa, V. Sneller. Journal of Clinical Oncology, 2010
814 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/c44aea08e4c6a124b5166e829bb8212d7d5fb493
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- EAU guidelines on renal cell carcinoma: 2014 update. (2010, positive): “Pivotal phase 3 trials have established sunitinib and bevacizumab plus IFN-a as first-line treatment options in treatment-naı̈ve patients with cc-mRCC and good to intermediate risk [71,72].”
- Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Two Phase III studies, CALGB 90206 and AVOREN, found that the addition of bevacizumab to interferon-α2a (IFNα2a) significantly improved PFS 83,84 (TABLE 1) , supporting this combination as first-line treatment in patients with metastatic renal cell carcinoma.”
- Molecular mechanisms and clinical applications of angiogenesis (2011, background): “In a recent trial, bevacizumab prolonged disease-free progression but not overall survival in patients with metastatic RC”
- Systemic therapy in metastatic renal cell carcinoma (2016, background): “In summary, treatment options for mRCC have expanded enormously, since the introduction of targeted therapies, and have significantly extended the survival of mRCC patients—OS can be prolonged by up to 32 months by sequencing different approved targeted drugs [20, 23, 39]—but the availability of num”
- ANTIANGIOGENESIS STRATEGIES REVISITED: FROM STARVING TUMORS TO ALLEVIATING HYPOXIA (2014, positive): “Moreover, a phase II clinical trial with dual HER2 blockade and bevacizumab showed encouraging results in heavily pretreated HER2+ breast cancer patients with brain metastases (Falchook et al., 2013).”